Amgen and UCB resubmit BLA for EVENITY to transform osteoporosis treatment in postmenopausal women
Amgen, in collaboration with UCB, has announced the resubmission of the biologics license application (BLA) for their osteoporosis drug candidate, EVENITY (romosozumab), to the US Food and Drug Administration (FDA). This resubmission is targeted at the treatment of osteoporosis in postmenopausal women who are at high risk of fractures, marking a significant development in the […]